TMRC Co.,Ltd.

Japanese

  • Home
  • About us
  • Business areas
  • Contact us

NEWS & Topics

2022.04.13 Research group led by researchers at Dept. of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, published in"Oncogene" on the effect of TM-411 to ameliorate the susceptibility of chemotherapy to pancreatic cancer.
2022.02.03 FDA designated TM-411 for MDS as an Orphan Drug.
2021.09.10 First patient enrolled in Phase II clinical trial of TM-411 in triplet combination with venetoclax and azacitidine for AML in US.

more info

Focusing on cancer!
Business areas

Company Overview
(c)2022 TMRC Co.Ltd All Rights Reserved.